P2RX7 His155Tyr — A Gain-of-Function Variant That Amplifies Neuroinflammation
The P2X7 receptor is an ATP-gated ion channel | The receptor opens when extracellular ATP
concentrations are high — a danger signal released by damaged or dying cells — triggering
inflammatory cascades expressed abundantly on
microglia, the brain's resident immune cells. When activated, P2X7 sets off the NLRP3
inflammasome, a molecular alarm system that releases the inflammatory cytokines IL-1β and
IL-18. The His155Tyr variant (rs208294, also notated c.489C>T in older references) causes
increased receptor protein expression | In vitro studies show that Tyr155 receptors accumulate
at higher levels on the cell surface, with both ion channel and pore functions scaling
proportionally — more receptors means stronger
inflammatory signaling in response to each stress signal. This gain-of-function effect places
carriers at a higher neuroinflammatory baseline and contributes to mood vulnerability,
pain sensitization, and altered immune responsiveness.
The Mechanism
The His155Tyr substitution occurs in exon 5 of P2RX7 | His155 encodes histidine in the
extracellular domain; the Tyr155 (T allele) variant is the ancestral form that predates
the modern reference sequence, within
the extracellular domain of the receptor. Western blotting confirmed that the Tyr155 gain-of-function
receptors are expressed at higher levels than the His155 form — the functional effect is driven
by receptor abundance rather than altered channel kinetics. More P2X7 receptors on microglial
and immune cell surfaces means a proportionally stronger ATP-induced response | Enhanced
calcium influx, greater potassium efflux, and heightened NLRP3 inflammasome assembly all
scale with surface receptor density: more calcium
influx, more potassium efflux, and a lower effective threshold for NLRP3 inflammasome
activation. The result is that the same tissue stress stimulus produces more IL-1β and IL-18
release. In the brain, this translates to a more reactive microglial state — one that is more
prone to neuroinflammation under psychological stress, infection, or metabolic challenge.
The Evidence
Pain sensitivity: In a study of patients with diabetic peripheral neuropathic pain | Sex-stratified
analysis of 156 non-Hispanic Caucasian subjects,
the Tyr155 (T) gain-of-function allele was associated with significantly higher pain intensity
scores in female patients (p=0.039). Male patients showed no significant association. This
sex-specific effect suggests estrogen–P2X7 interactions may amplify the gain-of-function
phenotype in women. The Tyr155 variant was also studied in post-mastectomy pain and
osteoarthritis cohorts, with mixed but directionally consistent findings.
Mood disorders: A prospective study of 450 patients with major depressive disorder or
bipolar disorder followed for a median of 60 months | Three independent cohorts with consistent
findings found rs208294 significantly elevated
familial mood disorder risk (OR 1.35, 95% CI 1.13–1.61, P=0.0013) and predicted more time
spent ill, with homozygous T carriers spending 12% more time in mood episodes than C/C
carriers. A follow-up structural equation study with 424 patients | Bootstrap-based mediation
test, P=0.02 showed that the T allele works
through elevated neuroticism — a personality trait capturing emotional reactivity and
sensitivity to negative stimuli — which in turn drives a higher proportion of time in
depressive and manic episodes. Importantly, not all studies replicate this association:
one study of 119 treatment-resistant MDD patients found no association between rs208294
and depression diagnosis or SSRI/ECT remission | May reflect heterogeneity across severity
spectra, and the evidence for mood disorders
overall remains moderate rather than strong.
Infection severity: The gain-of-function T allele activates a heightened inflammatory
response. During viral infections, this can become harmful. A 2024 study found that
homozygous TT genotype was approximately six times more likely in patients with severe
COVID-19 | Binary logistic regression; TT vs. CT+CC, p=0.022, OR=5.93, 95% CI 1.30–27.14
in an Italian cohort compared to mild cases,
consistent with excessive P2X7-driven cytokine release during acute infection.
Bone health: In a cohort of 921 Dutch fracture patients | Additive genetic model,
p=0.027, carriers of the Tyr155 T allele had
reduced femoral neck bone mineral density compared to His155 carriers — an unexpected finding
given gain-of-function predictions, but consistent with reports that chronic, low-grade
P2X7 overactivation can impair osteoblast function.
Practical Implications
The gain-of-function nature of this variant means that any process that releases extracellular
ATP — injury, hypoxia, intense psychological stress, or infection — will produce a stronger
inflammatory cascade in T allele carriers. For most daily situations, this difference is
unlikely to be noticeable. The clinical relevance is greatest for TT homozygotes and in
contexts of elevated inflammatory load: severe infection, chronic pain conditions, and prolonged
psychological stress. The mood disorder data is the most consistent finding and is mechanistically
coherent: excess microglial IL-1β interferes with serotonin synthesis, disrupts synaptic
plasticity, and increases HPA axis reactivity. Anti-inflammatory strategies — specifically
those targeting the IL-1β/NLRP3 pathway — are in clinical trials for treatment-resistant
depression, and this variant is likely to predict responsiveness to such approaches as the
evidence matures.
Interactions
Rs208294 (His155Tyr, gain-of-function) and rs3751143 (Glu496Ala, loss-of-function) have
opposite effects on P2X7 activity. Individuals carrying both variants have partially
offsetting functional consequences — the net impact on pain, inflammation, and immune
function depends on which alleles are present at each locus. A third gain-of-function
variant, rs1718119 (Ala348Thr), can compound the effect of rs208294 in individuals who
carry both T alleles. Rs7958311 (Arg270His) adds further complexity, with unique effects
on channel vs. pore function. Within the mood disorder pathway, P2X7's downstream NLRP3
inflammasome intersects with the NR3C1 glucocorticoid receptor (see rs2963154, rs10515522)
— stress hormone signaling and purinergic neuroinflammation converge on microglial
activation and synaptic plasticity.
All Genotypes
His155 variant with lower P2X7 receptor surface density and standard inflammatory signaling
You carry two copies of the C allele (His155), which produces P2X7 receptors at standard surface density. This genotype is the most common globally, found in about 30% of people. Your P2X7 signaling responds to ATP danger signals at a baseline level — not elevated, but not absent either. The neuroinflammatory pathway operates normally, and you do not carry the gain-of-function amplification associated with the T allele.
One gain-of-function allele producing intermediate P2X7 receptor expression and elevated neuroinflammatory potential
You carry one copy of the gain-of-function T allele (Tyr155) and one C allele (His155). This is the most common genotype, found in about 50% of people. Your P2X7 receptor expression is intermediate — somewhat above baseline, but not at the full two-copy gain. The effect on mood vulnerability and pain is additive: you likely have a modestly elevated neuroinflammatory response under stress compared to CC carriers, with a meaningful but not dramatic increase in mood disorder risk. In female carriers, there may be some increase in pain sensitivity in neuropathic pain conditions.
Two gain-of-function alleles producing elevated P2X7 receptor expression and heightened neuroinflammatory signaling
You carry two copies of the Tyr155 T allele, the gain-of-function form of P2X7. This genotype is found in about 20% of people globally. Your P2X7 receptors are expressed at higher density on microglial and immune cell surfaces, resulting in a more sensitive and amplified inflammatory response to ATP danger signals. The clinical implications span mood disorder vulnerability, pain sensitization in women, greater severity in viral infections, and modestly lower bone mineral density. The risk is probabilistic and context-dependent — in a low-stress, low-inflammatory environment the phenotype may be nearly invisible, but under immune challenge or chronic psychological stress the amplified neuroinflammation becomes clinically relevant.